drug-dev.com
Actinium Advances Iomab-B Towards Phase III | News | drug development and delivery current news | Drug Development & Delivery
http://www.drug-dev.com/Main/Current-News/1384.aspx
Actinium Advances Iomab-B Towards Phase III. We are optimistic that we will move through the meeting and application process successfully and obtain approval from the FDA that will allow us to move into the critical Phase III phase for Iomab-B, noted Kaushik J. Dave, President and Chief Executive Officer of Actinium Pharmaceuticals. We have also begun to establish the infrastructure necessary to enable speedy Phase 3 development of Iomab-B, if and when we receive IND status.". Ajinomoto Althea, Inc.
drug-dev.com
FORMULATION DEVELOPMENT - Overcoming Early Phase Development Challenges & Optimizing Formulations With a Minimal Amount of API | Articles | drug development and delivery back issues | Drug Development & Delivery
http://www.drug-dev.com/Main/Back-Issues/FORMULATION-DEVELOPMENT-Overcoming-Early-Phase-Dev-939.aspx
June 2015, Posted Date:. FORMULATION DEVELOPMENT - Overcoming Early Phase Development Challenges and Optimizing Formulations With a Minimal Amount of API. Softgel technology not only enables improved delivery of poorly soluble BCS Class II and IV drugs, but in cases where solubility is not the only biopharmaceutical hurdle to overcome, membrane modulation permeability can also be manipulated, thereby enabling the delivery of macromolecular BCS Class III drugs. The basic principles of LBDDS. Membrane....
specialtypharma.com
Sigma-Aldrich's $17-Billion Buy-Out Seen as Boost for Lab Suppliers | News | drug development and delivery current news | Drug Development & Delivery
http://www.specialtypharma.com/Main/Current-News/1388.aspx
Sigma-Aldrich's $17-Billion Buy-Out Seen as Boost for Lab Suppliers. The large premium Germany's Merck KGaA (MRCG.DE) agreed to pay in a $17-billion (10.37 billion pounds) acquisition of Sigma-Aldrich Corp (SIAL.O) shines a spotlight on, and potentially raises the value of, a company Merck discarded a decade ago. The recently announced Sigma-Aldrich deal not only raises awareness of consolidation in that segment of the life sciences sector, but "raises the value of VWR," Knight said. While molecular diag...
specialtypharma.com
Cristal Therapeutics & PX Biosolutions to Develop Innovative Vaccines | News | drug development and delivery current news | Drug Development & Delivery
http://www.specialtypharma.com/Main/Current-News/1386.aspx
Cristal Therapeutics and PX Biosolutions to Develop Innovative Vaccines. Cristal Therapeutics, a privately-held life sciences company developing innovative products against cancer and other diseases, by using its patented nanotechnology platforms, recently announced the start of a collaboration with PX Biosolutions. The joint research and development is focussed on the application of Cristal Therapeutics’ vaccine technology CriVac for the design of innovative vaccines. Joost Holthuis, CEO of Cristal Ther...
specialtypharma.com
Quotient Clinical Announces Expansion of Pharmaceutical Sciences capacity | News | drug development and delivery current news | Drug Development & Delivery
http://www.specialtypharma.com/Main/Current-News/1387.aspx
Quotient Clinical Announces Expansion of Pharmaceutical Sciences capacity. Quotient Clinical, the Translational Pharmaceutics Company, has announced a significant expansion of its pharmaceutical sciences capabilities, doubling capacity through the acquisition of a second GMP manufacturing facility and the construction of new formulation development and pharmaceutical analysis laboratories. This record has been viewed 2436. Ajinomoto Althea, Inc. Minnesota Rubber and Plastics. September 12-13, 2016.
specialtypharma.com
IONTOPHORESIS - Captisol-Enabled(TM) Lipophilic Drug Complex Delivered Transdermally by Iontophoresis | Articles | drug development and delivery back issues | Drug Development & Delivery
http://www.specialtypharma.com/Main/Back-Issues/IONTOPHORESIS-CaptisolEnabledTM-Lipophilic-Drug-Co-942.aspx
June 2015, Posted Date:. IONTOPHORESIS - Captisol-Enabled(TM) Lipophilic Drug Complex Delivered Transdermally by Iontophoresis. It is well known that the drugs with log P 1-3 (moderately lipophilic) and molecular weight of 500 Da have shown good permeability across the skin. A polyanionic modified cyclodextrin as a drug transport enhancer for lipophilic drugs. Captisol (Betadex Sulfobutyl Ether Sodium) was provided. As a gift from Ligand Pharmaceuticals (La Jolla, CA). Ibuprofen. Solubility measurements ...
specialtypharma.com
CLINICAL TRIALS - Accelerating the Clinical Trials Process | Articles | drug development and delivery back issues | Drug Development & Delivery
http://www.specialtypharma.com/Main/Back-Issues/CLINICAL-TRIALS-Accelerating-the-Clinical-Trials-P-943.aspx
June 2015, Posted Date:. CLINICAL TRIALS - Accelerating the Clinical Trials Process. The drug research and development process is a marathon. The journey from concept to FDA approval to availability typically takes upward of a decade and can cost somewhere in the neighborhood of a billion dollars. Pharmaceutical organizations are faced with time and cost complexities throughout the process, including Phase I through Phase IV clinical trials. IDENTIFYING and UNDERSTANDING CLINICAL TRIALS CHALLENGES. Clini...
specialtypharma.com
Catalent's Proprietary Softgel Technology Used to Provide Daily Dosing of Modified-Release Semi-Solid Formulation | News | drug development and delivery current news | Drug Development & Delivery
http://www.specialtypharma.com/Main/Current-News/1389.aspx
Catalent's Proprietary Softgel Technology Used to Provide Daily Dosing of Modified-Release Semi-Solid Formulation. Catalent Pharma Solutions recently welcomed the announcement by OPKO Health that the US Food and Drug Administration has accepted for review OPKO’s New Drug Application for a new treatment for chronic kidney disease (CKD) and vitamin D insufficiency, which uses Catalent’s proprietary OptiShell softgel technology as its delivery platform. Rayaldee represents the first time that a semi-solid f...
specialtypharma.com
EXTERNAL DELIVERY - Successful Business Failures | Articles | drug development and delivery back issues | Drug Development & Delivery
http://www.specialtypharma.com/Main/Back-Issues/EXTERNAL-DELIVERY-Successful-Business-Failures-960.aspx
July/August 2015, Posted Date:. EXTERNAL DELIVERY - Successful Business Failures. The obvious potential outcome from a business failure are job losses; brand damage; customer and vendor losses; a Chapter 7, Chapter 13, or a Chapter 11 bankruptcy; an auction, a liquidation, or a 363 pre-pack sale. What’s not so obvious are the benefits that can be derived from a business failure. I once read that success does not breed success. It breeds failure. It is failure that breeds success. Another major positive b...
